Multiple System Atrophy clinical trials at University of California Health

9 in progress, 5 open to eligible people

Showing trials for

  • TAK-341 in Treatment of Multiple System Atrophy

    open to eligible people ages 40 years and up

    The main aim is to see how TAK-341 works after 52 weeks in participants with multiple system atrophy as measured by the Unified Multiple System Atrophy Rating Scale Part I (UMSARS). The study will enroll approximately 138 patients. Participants will receive a total of 13 intravenous infusions every 4 weeks approximately, these may be either of TAK-341 or placebo, after each infusion some blood samplings will be taken and other assessments completed. This trial will be conducted in North America, Europe and Asia.

    at UCLA

  • GDNF Gene Therapy for Multiple System Atrophy

    open to eligible people ages 35-75

    The objective of this randomized, double-blinded, placebo-controlled Phase 1 investigation is to evaluate the safety and potential clinical effect of AAV2-GDNF delivered to the putamen in subjects with either a possible or probable diagnosis of Multiple System Atrophy.

    at UC Irvine

  • Parkinson's And Zoledronic Acid

    open to eligible people ages 60 years and up

    This home-based study is a randomized (1:1) placebo-controlled trial of a single infusion of zoledronic acid-5 mg (ZA) for the prevention of fractures in men and women aged 60 years and older with Parkinson's disease and parkinsonism with at least 2 years of follow-up. A total of 3500 participants will be enrolled and randomized in the United States. Participants, follow-up outcome assessors, and study investigators will be blinded to assigned study treatment. This trial is funded by the National Institute of Aging.

    at UC Davis UC Irvine UCLA UCSF

  • Automated Imaging Differentiation of Parkinsonism

    open to eligible people ages 40-80

    The purpose of this study is to test the performance of the AID-P across 21 sites in the Parkinson Study Group. Each site will perform imaging, clinical scales, diagnosis, and will upload the data to the web-based software tool. The clinical diagnosis will be blinded to the diagnostic algorithm and the imaging diagnosis will be compared to the movement disorders trained neurologist diagnosis.

    at UCSD UCSF

  • Pre-Gene Therapy Study in Parkinson's Disease and Multiple System Atrophy

    open to eligible people ages 35-75

    The objective of this study is to describe disease progression in study participants diagnosed with early Parkinson's Disease or Multiple System Atrophy - Parkinsonian Type up to 18 months as delineated by clinical and biochemical parameters.

    at UC Irvine

  • Lu AF82422 in Participants With Multiple System Atrophy

    Sorry, in progress, not accepting new patients

    To find out the effect of Lu AF82422 on disease progression in participants with multiple system atrophy.

    at UCSD UCSF

  • Durability of Ampreloxetine for the Treatment of Symptomatic nOH in Participants With Multiple System Atrophy

    Sorry, not currently recruiting here

    This is a Phase 3, multi-center, randomized withdrawal study to evaluate the efficacy and durability of ampreloxetine in participants with MSA and symptomatic nOH after 20 weeks of treatment. This study includes 4 periods: Screening, open label, randomized withdrawal, and long-term treatment extension (LTE).

    at UCSD

  • ATH434 in Participants With Multiple System Atrophy

    Sorry, in progress, not accepting new patients

    This study will assess the safety and efficacy of ATH434 in participants with Multiple System Atrophy

    at UCSD

  • North American Prodromal Synucleinopathy Consortium Stage 2

    Sorry, not currently recruiting here

    This study will enroll participants with idiopathic REM sleep behavior disorder (RBD) and healthy controls for the purpose of preparing for a clinical trial of neuroprotective treatments against synucleinopathies.

    at UCLA

Our lead scientists for Multiple System Atrophy research studies include .

Last updated: